• Colm Kerr, Niamh Allen, Gerry Hughes, Martina Kelly, Fiona O'Rourke, Yvonne Lynagh, Jean Dunne, Brendan Crowley, Niall Conlon, and Colm Bergin.
• Department of Infectious Diseases, St. James's Hospital, Dublin, Ireland. colmkerr@gmail.com.
• Ir J Med Sci. 2022 Jun 1; 191 (3): 108910921089-1092.

IntroductionSerological SARS-CoV-2 assays have an important role in guiding the pandemic response. This research aimed to compare the performance of 2 antinucleocapsid assays.MethodsSerum from 49 HCWs was analysed at baseline and 6 months using the Abbott diagnostics SARS-CoV-2 IgG assay and the Roche Diagnostics Elecsys Anti-SARS-CoV-2 total antibody assay.ResultsAt baseline, 14/49 participants (29%) demonstrated antibody reactivity using the Abbott assay. At 6 months, 4/14 participants (29%) continued to demonstrate reactivity. A total of 14/49 (29%) participants had detectable antibodies at baseline using the Roche assay. In total, 13/14 (93%) of participants demonstrated antibody reactivity at 6 months. The Abbott assay showed a statistically significant difference in the signal-to-threshold values of baseline reactive samples when repeated at 6 months (p = 0.001). This was not seen with the Roche assay (p = 0.51).ConclusionIn this small study, the Roche Diagnostics Elecsys Anti-SARS-CoV-2 total antibody assay appears superior in performance to the Abbott diagnostics SARS-CoV-2 IgG assay in accurately detecting participants with a history of confirmed COVID-19 disease at 6 months follow-up. This finding should be born in mind in the planning of future seroprevalence studies, especially when considering the use of anti-nucleocapsid assays.© 2021. The Author(s).

13 keywords...

hide…